Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

Phase 4 Recruiting 1200 enrolled Tulane University Healthcare Clinical Data · collab Louisiana State University Health Sciences Center in New Orleans · collab University of Alabama at Birmingham · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.

Timeline

Start: 2025-05-06
Primary completion: 2029-05-01
Completion: 2029-07-31

Publications

Muzny CA, Lillis RA, Chavoustie SE, Arbuckle JL, Van Gerwen OT, Sagoe M, Kandregula AR, Srivastav S, Kissinger PJ. Refining Trichomonas vaginalis treatment in women and men: protocol for an open-label randomised comparison of multi-dose oral metronidazole versus single-dose oral secnidazole. BMJ Open. 2026 Apr 24;16(4):e116003. doi: 10.1136/bmjopen-2025-116003.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metronidazole	Small molecule	500 mg	Oral
Subject	Secnidazole	Small molecule	2000 mg	Oral

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

Summary

Timeline

Publications

Drugs

Indications